Arcutis Biotherapeutics reported quarterly EPS of -$0.09, missing the Zacks Consensus Estimate of -$0.02 by $0.07 per share. The loss was still narrower than the -$0.20 per share reported a year ago, indicating year-over-year improvement despite the earnings miss. The print is modestly negative and likely to matter mainly to ARQT shares rather than the broader market.
Arcutis Biotherapeutics reported quarterly EPS of -$0.09, missing the Zacks Consensus Estimate of -$0.02 by $0.07 per share. The loss was still narrower than the -$0.20 per share reported a year ago, indicating year-over-year improvement despite the earnings miss. The print is modestly negative and likely to matter mainly to ARQT shares rather than the broader market.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
